| (Values in U.S. Thousands) | Sep, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 | Sep, 2023 |
| Sales | 116,190 | 114,570 | 91,410 | 109,740 | 93,100 |
| Sales Growth | +1.41% | +25.34% | -16.70% | +17.87% | +0.23% |
| Net Income | -20 | 6,900 | -19,110 | 6,570 | 3,930 |
| Net Income Growth | -100.29% | +136.11% | -390.87% | +67.18% | +153.54% |
Axonics Inc
(AXNX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Axonics Modulation Technologies Inc. is focused on development and commercialization of a novel implantable SNM system for patients with urinary and bowel dysfunction and disrupting the SNM market. Axonics Modulation Technologies Inc. is based in Irvine, CA.
Fiscal Year End Date: 12/31